New drug Kylo-12 enters first human safety trial for high cholesterol fats
NCT ID NCT06783881
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called Kylo-12 in 50 healthy volunteers to see if it is safe and how the body processes it. The drug aims to lower high triglycerides, a type of fat in the blood linked to heart problems. Participants receive either a single shot of Kylo-12 or a placebo, and researchers monitor for side effects and measure drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Kylo-12
- What this could lead to
- If successful, this could lead to a new treatment option for people with high triglycerides, a condition that raises heart disease risk.
- What could go wrong
- This is a very early Phase 1 trial in only 50 healthy people, so it is not yet known if Kylo-12 works or is safe long-term. Side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTRIGLYCERIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chengdu Xinhua Hospital
Chengdu, Sichuan, 610000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Plant-Based protein switch reshape your metabolism?
- Fish oil pills put to the test: can they tame high triglycerides?
- Weekly shot aims to tame dangerous fat levels in the blood
- Could ozempic stop pancreatitis from coming back?
- New shot aims to tame dangerous fat levels in blood
- New drug RBD5044 aims to lower high triglycerides in phase 2 trial